Brokerages Set Hologic, Inc. (NASDAQ:HOLX) PT at $79.31

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned a consensus recommendation of “Hold” from the sixteen analysts that are covering the stock, Marketbeat reports. Thirteen research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $79.3077.

A number of research analysts have recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and raised their target price for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. Leerink Partners upped their price target on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research note on Friday, November 21st. Finally, Evercore ISI cut Hologic from an “outperform” rating to an “in-line” rating and lowered their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th.

Hologic Stock Down 0.1%

HOLX stock opened at $75.10 on Monday. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The company’s 50-day moving average price is $74.86 and its 200 day moving average price is $70.75. Hologic has a 52 week low of $51.90 and a 52 week high of $75.36. The company has a market cap of $16.77 billion, a P/E ratio of 30.28, a P/E/G ratio of 2.13 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $1.01 EPS. On average, research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Trading of Hologic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic during the 2nd quarter worth about $26,000. Winnow Wealth LLC purchased a new position in shares of Hologic during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares during the period. Root Financial Partners LLC acquired a new stake in Hologic during the third quarter worth approximately $27,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in Hologic in the 4th quarter worth approximately $27,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.